-$0.50 Earnings Per Share Expected for Allakos Inc (NASDAQ:ALLK) This Quarter

Share on StockTwits

Equities analysts forecast that Allakos Inc (NASDAQ:ALLK) will report earnings of ($0.50) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Allakos’ earnings, with the lowest EPS estimate coming in at ($0.50) and the highest estimate coming in at ($0.49). Allakos posted earnings per share of ($0.35) during the same quarter last year, which would suggest a negative year-over-year growth rate of 42.9%. The company is expected to issue its next earnings results on Thursday, March 12th.

On average, analysts expect that Allakos will report full year earnings of ($1.88) per share for the current fiscal year, with EPS estimates ranging from ($1.88) to ($1.87). For the next year, analysts anticipate that the business will report earnings of ($2.58) per share, with EPS estimates ranging from ($2.98) to ($2.17). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Allakos.

Allakos (NASDAQ:ALLK) last issued its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.04).

Several equities analysts have commented on the stock. ValuEngine lowered shares of Allakos from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research downgraded shares of Allakos from a “buy” rating to a “hold” rating in a research report on Friday, August 16th. Finally, William Blair reaffirmed a “buy” rating on shares of Allakos in a research report on Friday, August 9th.

Shares of NASDAQ ALLK traded down $7.16 during midday trading on Tuesday, hitting $115.90. 608,969 shares of the company’s stock were exchanged, compared to its average volume of 449,455. The firm’s fifty day simple moving average is $80.42 and its 200-day simple moving average is $64.83. The company has a market cap of $6.70 billion, a PE ratio of -52.68 and a beta of -1.13. Allakos has a twelve month low of $30.32 and a twelve month high of $139.99.

A number of hedge funds and other institutional investors have recently modified their holdings of ALLK. Tower Research Capital LLC TRC bought a new position in Allakos in the 3rd quarter valued at about $42,000. Bank of Montreal Can bought a new position in shares of Allakos in the second quarter valued at approximately $63,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Allakos during the third quarter worth $113,000. Amundi Pioneer Asset Management Inc. purchased a new stake in Allakos in the 1st quarter valued at $142,000. Finally, Metropolitan Life Insurance Co NY grew its stake in shares of Allakos by 66.5% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 4,931 shares of the company’s stock worth $199,000 after acquiring an additional 1,970 shares in the last quarter. 68.68% of the stock is currently owned by hedge funds and other institutional investors.

Allakos Company Profile

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Featured Article: The role of implied volatility with call option volume

Get a free copy of the Zacks research report on Allakos (ALLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allakos (NASDAQ:ALLK)

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.